Literature DB >> 27612625

Embolic Stroke of Undetermined Source and Detection of Atrial Fibrillation on Follow-Up: How Much Causality Is There?

George Ntaios1, Vasileios Papavasileiou2, Gregory Y H Lip3, Haralampos Milionis4, Konstantinos Makaritsis5, Anastasia Vemmou6, Eleni Koroboki6, Efstathios Manios6, Konstantinos Spengos7, Patrik Michel8, Konstantinos Vemmos6.   

Abstract

BACKGROUND: There is increasing debate whether atrial fibrillation (AF) episodes during follow-up in patients with embolic stroke of undetermined source (ESUS) are causally associated with the event. AF-related strokes are more severe than strokes of other etiologies. In this context, we aimed to compare stroke severity between ESUS patients diagnosed with AF during follow-up and those who were not. We hypothesized that, if AF episodes detected during follow-up are indeed causally associated with the index event, stroke severity in the AF group should be higher than the non-AF group.
METHODS: Dataset was derived from the Athens Stroke Registry. ESUS was defined by the Cryptogenic Stroke/ESUS International-Working-Group criteria. Stroke severity was assessed by the National Institutes of Health Stroke Scale (NIHSS) score. Cumulative probabilities of recurrent stroke or peripheral embolism in the AF and non-AF ESUS groups were estimated by Kaplan-Meier analyses.
RESULTS: Among 275 ESUS patients, AF was detected during follow-up in 80 (29.1%), either during repeated electrocardiogram monitoring (18.2%) or during hospitalization for stroke recurrence (10.9%). NIHSS score was similar between the two groups (5 [2-13] versus 5 [2-14], P = .998). More recurrent strokes or peripheral embolisms occurred in the AF group compared with the non-AF group (42.5% versus 13.3%, P = .001).
CONCLUSIONS: Stroke severity is similar between ESUS patients who were diagnosed with AF during follow-up and those who were not. Given that AF-related strokes are more severe than strokes of other etiologies, this finding challenges the assumption that the association between ESUS and AF detected during follow-up is as frequently causal as regarded.
Copyright © 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Stroke; atrial fibrillation; embolism; stroke severity

Mesh:

Year:  2016        PMID: 27612625     DOI: 10.1016/j.jstrokecerebrovasdis.2016.08.015

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  5 in total

1.  Atrial cardiopathy in embolic stroke of undetermined source.

Authors:  Jing Chen; Fenglian Gao; Wenhong Liu
Journal:  Brain Behav       Date:  2021-05-04       Impact factor: 2.708

2.  Usefulness of P Wave Duration in Embolic Stroke of Undetermined Source.

Authors:  Moonki Jung; Jin-Seok Kim; Ju Hyeon Song; Jeong-Min Kim; Kwang-Yeol Park; Wang-Soo Lee; Sang Wook Kim; Gregory Yh Lip; Seung Yong Shin
Journal:  J Clin Med       Date:  2020-04-15       Impact factor: 4.241

3.  Prevalence and Overlap of Potential Embolic Sources in Patients With Embolic Stroke of Undetermined Source.

Authors:  George Ntaios; Kalliopi Perlepe; Dimitrios Lambrou; Gaia Sirimarco; Davide Strambo; Ashraf Eskandari; Efstathia Karagkiozi; Anastasia Vemmou; Eleni Koroboki; Efstathios Manios; Konstantinos Makaritsis; Konstantinos Vemmos; Patrik Michel
Journal:  J Am Heart Assoc       Date:  2019-07-31       Impact factor: 5.501

4.  Left Atrial Dynamics Is Altered in Young Adults With Cryptogenic Ischemic Stroke: A Case-Control Study Utilizing Advanced Echocardiography.

Authors:  Jani Pirinen; Vesa Järvinen; Nicolas Martinez-Majander; Juha Sinisalo; Pauli Pöyhönen; Jukka Putaala
Journal:  J Am Heart Assoc       Date:  2020-03-25       Impact factor: 5.501

5.  Recurrent Stroke Incidence and Etiology in Patients with Embolic Stroke of Undetermined Source and Other Stroke Subtypes.

Authors:  Sono Toi; Yuka Shirai; Kentaro Ishizuka; Megumi Hosoya; Misa Seki; Eiko Higuchi; Takao Hoshino; Kazuo Kitagawa
Journal:  J Atheroscler Thromb       Date:  2021-02-18       Impact factor: 4.928

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.